Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 29;11(8):765.
doi: 10.3390/life11080765.

The Potential Role of Serotonergic Hallucinogens in Depression Treatment

Dominika Psiuk  1 , Emilia Nowak  1 , Krystian Cholewa  1 , Urszula Łopuszańska  1 , Marzena Samardakiewicz  1
Affiliations
Review

The Potential Role of Serotonergic Hallucinogens in Depression Treatment

Dominika Psiuk et al. Life (Basel). .

Abstract

Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic substances for the treatment of depression. A literature search of the PubMed/MEDLINE database identified 14 clinical trials from the last 10 years that examined the use of psilocybin, MDMA, DMT, or LSD for the treatment of depression symptoms. Some psychedelics, especially psilocybin, demonstrated an ability to reduce depressive symptoms as measured by several psychological scales, which was often sustained for months after the last psychedelic session. Moreover, one study revealed that psilocybin has comparable efficacy to escitalopram in the treatment of depression. None of the studies reported any serious adverse events associated with psychedelic administration. The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future.

Keywords: DMT; LSD; MDMA; depression; psilocybin; psychedelics; serotonergic hallucinogens.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Article selection process.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Depression. [(accessed on 19 April 2021)];2020 Available online: https://www.who.int/news-room/fact-sheets/detail/depression.
    1. Schmaal L., Pozzi E., Ho T.C., Van Velzen L.S., Veer I.M., Opel N., Van Someren E.J.W., Han L.K.M., Aftanas L., Aleman A., et al. ENIGMA MDD: Seven years of global neuroimaging studies of major depression through worldwide data sharing. Transl. Psychiatry. 2020;10:172. doi: 10.1038/s41398-020-0842-6. - DOI - PMC - PubMed
    1. Otte C., Gold S., Penninx B.W., Pariante C.M., Etkin A., Fava M., Mohr D., Schatzberg A.F. Major depressive disorder. Nat. Rev. Dis. Prim. 2016;2:16065. doi: 10.1038/nrdp.2016.65. - DOI - PubMed
    1. Penninx B.W.J.H., Milaneschi Y., Lamers F., Vogelzangs N. Understanding the somatic consequences of depression: Biological mechanisms and the role of depression symptom profile. BMC Med. 2013;11:129. doi: 10.1186/1741-7015-11-129. - DOI - PMC - PubMed
    1. Dong M., Zeng L.-N., Lu L., Li X.-H., Ungvari G.S., Ng C.H., Chow I.H.I., Zhang L., Zhou Y., Xiang Y.-T. Prevalence of suicide attempt in individuals with major depressive disorder: A meta-analysis of observational surveys. Psychol. Med. 2018;49:1691–1704. doi: 10.1017/S0033291718002301. - DOI - PubMed

LinkOut - more resources